EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Baseline Characteristics of Adult Patients Treated and Never Treated with Teduglutide in a Multinational Short Bowel Syndrome and Intestinal Failure Registry

Gabriel E Gondolesi, Ulrich-Frank Pape iD, Joel B Mason iD, Johane P Allard, Loris Pironi iD, María Núria Virgili Casas, Lauren K Schwartz, Francisca Joly, André Gabriel, Sasan Sabrdaran, Pinggao Zhang, Martina Kohl-Sobania und 2 weitere

Nutrients · 2024

DOI: 10.3390/nu16152513 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Nutrients, 2024. Verfasst von Gabriel E Gondolesi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Intestinal Failure, Rehabilitation and Transplant Unit, Hospital Universitario Fundación Favaloro, Buenos Aires C1044AAA, Argentina. Hauptthemen laut MEDLINE: Gastrointestinal Agents, Peptides, Registries, Short Bowel Syndrome. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Pharmaceuticals International, Inc., USA..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Short Bowel Syndrome (SBS) Registry (NCT01990040) is a multinational real-world study evaluating the long-term safety of teduglutide in patients with SBS and intestinal failure (SBS-IF) in routine clinical practice. This paper describes the study methodology and baseline characteristics of adult patients who have (ever-treated) or have never (never-treated) received teduglutide. A total of 1411 adult patients (679 ever-treated; 732 never-treated) were enrolled at 124 sites across 17 countries. The mean (standard deviation [SD]) age at enrollment was 55.4 (15.46) years, and 60.2% of patients were women. Crohn’s disease was the most common cause of major intestinal resection in both ever-treated (34.1%) and never-treated patients (20.4%). A similar proportion of ever-treated and never-treated patients had a prior history of colorectal polyps (2.7% vs. 3.6%), whereas proportionally fewer ever-treated patients reported a history of colorectal cancer (1.8% vs. 6.2%) or any malignancy (17.7% vs. 30.0%) than never-treated patients. Never-treated patients received a numerically greater mean (SD) volume of parenteral nutrition and/or intravenous fluids than ever-treated patients (12.4 [8.02] vs. 10.1 [6.64] L/week). Ever-treated patients received a mean teduglutide dosage of 0.05 mg/kg/day. This is the first report of patient baseline characteristics from the SBS Registry, and the largest cohort of patients with SBS-IF to date. Overall, ever-treated and never-treated patients had similar baseline characteristics. Differences between treatment groups may reflect variations in patient selection and degree of monitoring.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal AgentsPeptidesRegistriesShort Bowel SyndromeAdultAgedFemaleHumansMaleMiddle AgedCrohn DiseaseIntestinal FailureTreatment Outcome

Stichwörter der Autor:innen

Crohn’s diseaseGLP-2 analogsGattexRevestivecolorectal polypsintestinal failureparenteral nutritionreal-worldshort bowel syndrometeduglutide

Substanzen

Gastrointestinal AgentsPeptidesteduglutide

Autor:innen und Institutionen

  • Intestinal Failure, Rehabilitation and Transplant Unit, Hospital Universitario Fundación Favaloro, Buenos Aires C1044AAA, Argentina.
  • Asklepios Klinik St. Georg, Asklepios Medical School, 20099 Hamburg, Germany.
  • Department of Hepatology and Gastroenterology, Charité University Medicine Berlin, 13353 Berlin, Germany.
  • Tufts Medical Center, Tufts University, Boston, MA 02111, USA.
  • Toronto General Hospital, University of Toronto, Toronto, ON M5G 2C4, Canada.
  • Department of Medical and Surgical Sciences, University of Bologna, 40138 Bologna, Italy.

ORCID-Profile: Ulrich-Frank Pape, Joel B Mason, Loris Pironi, Yi-Wen Huang, Palle B Jeppesen

Förderung

  • Takeda Pharmaceuticals International, Inc., USA.

Zitieren

APA

Gondolesi, G. E., Pape, U. F., Mason, J. B., Allard, J. P., Pironi, L., Casas, M. N. V., Schwartz, L. K., Joly, F., Gabriel, A., Sabrdaran, S., Zhang, P., Kohl-Sobania, M., Huang, Y. W., & Jeppesen, P. B. (2024). Baseline Characteristics of Adult Patients Treated and Never Treated with Teduglutide in a Multinational Short Bowel Syndrome and Intestinal Failure Registry. Nutrients. https://doi.org/10.3390/nu16152513

Vancouver

Gondolesi GE, Pape UF, Mason JB, Allard JP, Pironi L, Casas MNV, et al. Baseline Characteristics of Adult Patients Treated and Never Treated with Teduglutide in a Multinational Short Bowel Syndrome and Intestinal Failure Registry. Nutrients. 2024. doi:10.3390/nu16152513

BibTeX
@article{Gondolesi2024,
  author = {Gondolesi, Gabriel E and Pape, Ulrich-Frank and Mason, Joel B and Allard, Johane P and Pironi, Loris and Casas, María Núria Virgili and Schwartz, Lauren K and Joly, Francisca and Gabriel, André and Sabrdaran, Sasan and Zhang, Pinggao and Kohl-Sobania, Martina and Huang, Yi-Wen and Jeppesen, Palle B},
  title = {Baseline Characteristics of Adult Patients Treated and Never Treated with Teduglutide in a Multinational Short Bowel Syndrome and Intestinal Failure Registry},
  journal = {Nutrients},
  year = {2024},
  doi = {10.3390/nu16152513}
}
Kostenlos starten →